Acambis completes delivery of 500,000 doses of MVA3000 smallpox vaccine to US Government
Acambis is co-developing MVA3000 with Baxter Healthcare SA ("Baxter"), which produced the 500,000 doses at its facilities and provides process development and manufacturing services.
In August, the Department of Health and Human Services issued a Request for Proposals (RFP) for the manufacture of up to 20 million doses of MVA attenuated smallpox vaccine and advanced clinical testing up to and including obtaining a product license for MVA. It also included options for the purchase of up to 60 million additional doses of MVA and "warm-base" manufacturing over the longer term. Acambis submitted a proposal in response to the RFP in October and the US Government has indicated that contract award(s) will be made in February 2006.
Organizations
Other news from the department research and development
These products might interest you
Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.